Methylomic Biomarkers of Lithium Response in Bipolar Disorder: A Proof of Transferability Study

Five Broad sets of Definitions of Globalization
Five Broad sets of Definitions of Globalization

Methylomic Biomarkers of Lithium Response in Bipolar Disorder: A Proof of Transferability Study



1. Introduction

2. Results

2.1. Optimization of the MS-HRM Tests

2.2. Consistency and Agreement between SeqCapEpi and MS-HRM DNA Methylation Measures (n = 23)

2.3. Performance of MS-HRM Assays in the Extended Sample (n = 70)

3. Discussion

4. Methods

4.1. Sample

4.2. Phenotyping of Response to Lithium

4.2.1. Original Alda Scale

4.2.2. Machine Learning Approach to Rating the Alda Scale

4.3. DNA Isolation and Bisulfite Modification

4.4. Methylation Sensitive High-Resolution Melting

4.5. Statistical Analysis

5. Conclusions

Supplementary Materials

Author Contributions


Institutional Review Board Statement

Informed Consent Statement

Data Availability Statement


Conflicts of Interest


  1. Collins, P.Y.; Patel, V.; Joestl, S.S.; March, D.; Insel, T.R.; Daar, A.S.; Bordin, I.A.; Costello, E.J.; Durkin, M.; Fairburn, C.G.; et al. Grand challenges in global mental health. Nature 2011, 475, 27–30. [Google Scholar] [CrossRef]
  2. Gore, F.M.; Bloem, P.J.; Patton, G.; Ferguson, J.; Joseph, V.; Coffey, C.; Sawyer, S.M.; Mathers, C.D. Global burden of disease in young people aged 10–24 years: A systematic analysis. Lancet 2011, 377, 2093–2102. [Google Scholar] [CrossRef]
  3. Can, A.; Schulze, T.G.; Gould, T.D. Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol. Biochem. Behav. 2014, 123, 3–16. [Google Scholar] [CrossRef] [PubMed][Green Version]
  4. Geddes, J.R.; Burgess, S.; Hawton, K.; Jamison, K.; Goodwin, G.M. Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiatry 2004, 161, 217–222. [Google Scholar] [CrossRef] [PubMed]
  5. Manchia, M.; Adli, M.; Akula, N.; Ardau, R.; Aubry, J.-M.; Backlund, L.; Banzato, C.E.; Baune, B.T.; Bellivier, F.; Bengesser, S.; et al. Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS ONE 2013, 8, e65636. [Google Scholar] [CrossRef] [PubMed][Green Version]
  6. Kessing, L.V.; Hellmund, G.; Andersen, P.K. Predictors of excellent response to lithium. Int. Clin. Psychopharmacol. 2011, 26, 323–328. [Google Scholar] [CrossRef]
  7. Laroche, D.G.; Etain, B.; Severus, E.; Scott, J.; Bellivier, F. Socio-demographic and clinical predictors of outcome to long-term treatment with lithium in bipolar disorders: A systematic review of the contemporary literature and recommendations from the ISBD/IGSLI Task Force on treatment with lithium On behalf of the ISBD-IGSLI Joint Task Force on Lithium Treatment. Int. J. Bipolar Disord. 2020, 8, 40. [Google Scholar] [CrossRef]
  8. Hui, T.P.; Kandola, A.; Shen, L.; Lewis, G.; Osborn, D.P.J.; Geddes, J.R.; Hayes, J.F. A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder. Acta Psychiatr. Scand. 2019, 140, 94–115. [Google Scholar] [CrossRef][Green Version]
  9. Scott, J.; Hidalgo-Mazzei, D.; Strawbridge, R.; Young, A.; Resche-Rigon, M.; Etain, B.; Andreassen, O.A.; Bauer, M.; Bennabi, D.; Blamire, A.M.; et al. Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: Overview of the H2020-funded R-LiNK initiative. Int. J. Bipolar Disord. 2019, 7, 20. [Google Scholar] [CrossRef][Green Version]
  10. Vecera, C.M.; Fries, G.R.; Shahani, L.R.; Soares, J.C.; Machado-Vieira, R. Pharmacogenomics of Lithium Response in Bipolar Disorder. Pharmaceuticals 2021, 14, 287. [Google Scholar] [CrossRef]
  11. Bellivier, F.; Marie-Claire, C. Molecular Signatures of Lithium Treatment: Current Knowledge. Pharmacopsychiatry 2018, 51, 212–219. [Google Scholar] [CrossRef] [PubMed]
  12. Hou, L.; Heilbronner, U.; Degenhardt, F.; Adli, M.; Akiyama, K.; Akula, N.; Ardau, R.; Arias, B.; Backlund, L.; Banzato, C.; et al. Genetic variants associated with response to lithium treatment in bipolar disorder: A genome-wide association study. Lancet 2016, 387, 1085–1093. [Google Scholar] [CrossRef][Green Version]
  13. Nunes, A.; Stone, W.; Ardau, R.; Berghöfer, A.; Bocchetta, A.; Chillotti, C.; Deiana, V.; Degenhardt, F.; Forstner, A.J.; Garnham, J.S.; et al. Exemplar scoring identifies genetically separable phenotypes of lithium responsive bipolar disorder. Transl. Psychiatry 2021, 11, 36. [Google Scholar] [CrossRef] [PubMed]
  14. Anand, A.; Nakamura, K.; Spielberg, J.M.; Cha, J.; Karne, H.; Hu, B. Integrative analysis of lithium treatment associated effects on brain structure and peripheral gene expression reveals novel molecular insights into mechanism of action. Transl. Psychiatry 2020, 10, 103. [Google Scholar] [CrossRef][Green Version]
  15. Reinbold, C.S.; Forstner, A.J.; Hecker, J.; Fullerton, J.; Hoffmann, P.; Hou, L.; Heilbronner, U.; Degenhardt, F.; Adli, M.; Akiyama, K.; et al. Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. Front. Psychiatry 2018, 387, 1085–1093. [Google Scholar] [CrossRef]
  16. Squassina, A.; Pisanu, C.; Corbett, N.; Alda, M. Telomere length in bipolar disorder and lithium response. Eur. Neuropsychopharmacol. 2017, 27, 560–567. [Google Scholar] [CrossRef]
  17. Squassina, A.; Pisanu, C.; Congiu, D.; Caria, P.; Frau, D.; Niola, P.; Melis, C.; Baggiani, G.; Lopez, J.P.; Cruceanu, C.; et al. Leukocyte telomere length positively correlates with duration of lithium treatment in bipolar disorder patients. Eur. Neuropsychopharmacol. 2016, 26, 1241–1247. [Google Scholar] [CrossRef]
  18. Martinsson, L.; Wei, Y.; Xu, D.; Melas, P.A.; Mathé, A.A.; Schalling, M.; Lavebratt, C.; Backlund, L. Long-term lithium treatment in bipolar disorder is associated with longer leukocyte telomeres. Transl. Psychiatry 2013, 3, e261. [Google Scholar] [CrossRef][Green Version]
  19. Moreira, J.; Noé, G.; Rangarajan, S.; Courtin, C.; Etain, B.; Geoffroy, P.A.; Laplanche, J.-L.; Vidal, M.; Bellivier, F.; Marie-Claire, C. Lithium effects on serine-threonine kinases activity: High throughput kinomic profiling of lymphoblastoid cell lines from excellent-responders and non-responders bipolar patients. World J. Biol. Psychiatry 2020, 21, 317–324. [Google Scholar] [CrossRef]
  20. Legrand, A.; Iftimovici, A.; Khayachi, A.; Chaumette, B. Epigenetics in bipolar disorder: A critical review of the literature. Psychiatr. Genet. 2021, 31, 1–12. [Google Scholar] [CrossRef]
  21. Shirvani-Farsani, Z.; Maloum, Z.; Bagheri-Hosseinabadi, Z.; Vilor-Tejedor, N.; Sadeghi, I. DNA methylation signature as a biomarker of major neuropsychiatric disorders. J. Psychiatr. Res. 2021, 141, 34–49. [Google Scholar] [CrossRef] [PubMed]
  22. Marie-Claire, C.; Lejeune, F.X.; Mundwiller, E.; Ulveling, D.; Moszer, I.; Bellivier, F.; Etain, B. A DNA methylation signature discriminates between excellent and non-response to lithium in patients with bipolar disorder type 1. Sci. Rep. 2020, 10, 1–9. [Google Scholar] [CrossRef]
  23. Wojdacz, T.K.; Dobrovic, A.; Hansen, L.L. Methylation-sensitive high-resolution melting. Nat. Protoc. 2008, 3, 1903–1908. [Google Scholar] [CrossRef]
  24. Šestáková, Š.; Šálek, C.; Remešová, H. DNA Methylation Validation Methods: A Coherent Review with Practical Comparison. Biol. Proced. Online 2019, 21, 19. [Google Scholar] [CrossRef] [PubMed]
  25. Ferreira, I.R.; Cunha, W.D.D.S.; Gomes, L.H.F.; Cintra, H.A.; Fonseca, L.L.C.G.; Bastos, E.F.; Llerena, J.C., Jr.; De Vasconcelos, Z.F.M.; Guida, L.D.C.; Llerena, J.C. A rapid and accurate methylation-sensitive high-resolution melting analysis assay for the diagnosis of Prader Willi and Angelman patients. Mol. Genet. Genom. Med. 2019, 7, e637. [Google Scholar] [CrossRef] [PubMed]
  26. Etain, B.; Mathieu, F.; Henry, C.; Raust, A.; Roy, I.; Germain, A.; Leboyer, M.; Bellivier, F. Preferential association between childhood emotional abuse and bipolar disorder. J. Trauma. Stress 2010, 23, 376–383. [Google Scholar] [CrossRef]
  27. Grof, P.; Duffy, A.; Cavazzoni, P.; Grof, E.; Garnham, J.; MacDougall, M.; O’Donovan, C.; Alda, M. Is response to prophylactic lithium a familial trait? J. Clin. Psychiatry 2002, 63, 942–947. [Google Scholar] [CrossRef]
  28. Scott, J.; Etain, B.; Manchia, M.; Brichant-Petitjean, C.; Geoffroy, P.A.; Schulze, T.; Alda, M.; Bellivier, F.; Amare, A.; Ardau, R.; et al. An examination of the quality and performance of the Alda scale for classifying lithium response phenotypes. Bipolar Disord. 2019, 22, 255–265. [Google Scholar] [CrossRef]
  29. Etain, B.; Meyrel, M.; Hennion, V.; Bellivier, F.; Scott, J. Can actigraphy be used to define lithium response dimensions in bipolar disorders? J. Affect. Disord. 2021, 283, 402–409. [Google Scholar] [CrossRef]
  30. Scott, J.; Geoffroy, P.A.; Sportiche, S.; Brichant-Petit-Jean, C.; Gard, S.; Kahn, J.-P.; Azorin, J.-M.; Henry, C.; Etain, B.; Bellivier, F. Cross-validation of clinical characteristics and treatment patterns associated with phenotypes for lithium response defined by the Alda scale. J. Affect. Disord. 2017, 208, 62–67. [Google Scholar] [CrossRef]
  31. Wojdacz, T.K.; Dobrovic, A. Methylation-sensitive high resolution melting (MS-HRM): A new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007, 35, e41. [Google Scholar] [CrossRef] [PubMed][Green Version]
  32. Wojdacz, T.K.; Hansen, L.L. Reversal of PCR bias for improved sensitivity of the DNA methylation melting curve assay. BioTechniques 2006, 41, 274–278. [Google Scholar] [CrossRef] [PubMed]
  33. Tse, M.Y.; Ashbury, J.E.; Zwingerman, N.; King, W.D.; Taylor, S.A.; Pang, S.C. A refined, rapid and reproducible high resolution melt (HRM)-based method suitable for quantification of global LINE-1 repetitive element methylation. BMC Res. Notes 2011, 4, 565. [Google Scholar] [CrossRef] [PubMed][Green Version]
  What is a Competency Model? Its Examples and Benefits
n (%)Median IQR
n *70
Alda total score6 (3–8)
Alda-based GR/PaR/NR18/32/20
Sex ratio Male/Female33/37
Age43 (35–53)
BMI24.5 (22.5–27.6)
Smokers yes/no33/35
Li current use yes/no63/7
Model 1 GR ≥ 8/NR ≤ 7 (Alda-based broad definition)18/52
Model 2 GR/NR (Algo-based)15/48
Model 3 GR ≥ 8/NR ≤ 3 (Alda-based strict definition)18/20

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (

Share and Cite

Marie-Claire, C.; Courtin, C.; Bellivier, F.; Scott, J.; Etain, B. Methylomic Biomarkers of Lithium Response in Bipolar Disorder: A Proof of Transferability Study. Pharmaceuticals 2022, 15, 133.

Marie-Claire C, Courtin C, Bellivier F, Scott J, Etain B. Methylomic Biomarkers of Lithium Response in Bipolar Disorder: A Proof of Transferability Study. Pharmaceuticals. 2022; 15(2):133.

  Atom | Definition, Structure, History, Examples, Diagram, & Facts

Chicago/Turabian Style

Marie-Claire, Cynthia, Cindie Courtin, Frank Bellivier, Jan Scott, and Bruno Etain. 2022. “Methylomic Biomarkers of Lithium Response in Bipolar Disorder: A Proof of Transferability Study” Pharmaceuticals 15, no. 2: 133.

Bạn đang xem bài viết: Methylomic Biomarkers of Lithium Response in Bipolar Disorder: A Proof of Transferability Study. Thông tin do THCS Nguyễn Thanh Sơn chọn lọc và tổng hợp cùng với các chủ đề liên quan khác.

Leave a Comment